CY1125161T1 - Ενωσεις 1,2,4-οξαδιαζολιου και θειαδιαζολιου ως ανοσορρυθμιστες - Google Patents

Ενωσεις 1,2,4-οξαδιαζολιου και θειαδιαζολιου ως ανοσορρυθμιστες

Info

Publication number
CY1125161T1
CY1125161T1 CY20221100154T CY221100154T CY1125161T1 CY 1125161 T1 CY1125161 T1 CY 1125161T1 CY 20221100154 T CY20221100154 T CY 20221100154T CY 221100154 T CY221100154 T CY 221100154T CY 1125161 T1 CY1125161 T1 CY 1125161T1
Authority
CY
Cyprus
Prior art keywords
oxadiazole
immuno
regulators
thiadiazole compounds
compounds
Prior art date
Application number
CY20221100154T
Other languages
English (en)
Inventor
Pottayil Govindan Nair Sasikumar
Muralidhara Ramachandra
Seetharamaiah Setty Sudarshan Naremaddepalli
Original Assignee
Aurigene Discovery Technologies Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Technologies Limited filed Critical Aurigene Discovery Technologies Limited
Publication of CY1125161T1 publication Critical patent/CY1125161T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε ενώσεις 1,2,4-οξαδιαζολίου του τύπου (Ι) και χρήση αυτών για να αναστέλλεται το μονοπάτι σηματοδότησης προγραμματισμένου θανάτου κυττάρου (PD1) ή/και για θεραπεία διαταραχών με αναστολή ανοσοκατασταλτικού σήματος που διεγείρεται με PD-1, PD-L1 ή PD-L2.
CY20221100154T 2015-03-10 2022-02-24 Ενωσεις 1,2,4-οξαδιαζολιου και θειαδιαζολιου ως ανοσορρυθμιστες CY1125161T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1180CH2015 2015-03-10
IN1178CH2015 2015-03-10
PCT/IB2016/051266 WO2016142833A1 (en) 2015-03-10 2016-03-07 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators

Publications (1)

Publication Number Publication Date
CY1125161T1 true CY1125161T1 (el) 2023-06-09

Family

ID=56879282

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100154T CY1125161T1 (el) 2015-03-10 2022-02-24 Ενωσεις 1,2,4-οξαδιαζολιου και θειαδιαζολιου ως ανοσορρυθμιστες

Country Status (27)

Country Link
US (3) US10781189B2 (el)
EP (2) EP3267984B1 (el)
JP (4) JP6815686B2 (el)
KR (1) KR20170123640A (el)
CN (4) CN107427477B (el)
AU (3) AU2016230793B2 (el)
CA (2) CA2979137C (el)
CU (1) CU24509B1 (el)
CY (1) CY1125161T1 (el)
DK (1) DK3267984T3 (el)
EA (1) EA034708B1 (el)
ES (1) ES2907988T3 (el)
HK (1) HK1247814A1 (el)
HR (1) HRP20220258T1 (el)
HU (1) HUE058274T2 (el)
IL (2) IL305546A (el)
LT (1) LT3267984T (el)
MX (2) MX2020003735A (el)
MY (1) MY196130A (el)
NZ (1) NZ734650A (el)
PH (1) PH12017501454A1 (el)
PL (1) PL3267984T3 (el)
PT (1) PT3267984T (el)
RS (1) RS62960B1 (el)
SG (2) SG11201706908PA (el)
SI (1) SI3267984T1 (el)
WO (1) WO2016142833A1 (el)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2893597C (en) 2012-12-07 2021-06-29 Chemocentryx, Inc. Diazole lactams
ES2788848T3 (es) 2013-09-06 2020-10-23 Aurigene Discovery Tech Ltd Derivados de 1,2,4-oxadiazol como inmunomoduladores
EA034708B1 (ru) 2015-03-10 2020-03-10 Ауриджен Дискавери Текнолоджис Лимитед 1,2,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов
PT3439653T (pt) 2016-04-07 2021-03-25 Chemocentryx Inc Redução da carga tumoral por administração de antagonistas de ccr1 em combinação com inibidores de pd-1 ou inibidores de pd-l1
WO2018047139A1 (en) * 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Compounds as modulators of tigit signalling pathway
WO2018051254A1 (en) * 2016-09-14 2018-03-22 Aurigene Discovery Technologies Limited Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators
DK3526323T3 (da) 2016-10-14 2023-06-26 Prec Biosciences Inc Modificerede meganucleaser der er specifikke for en genkendelsessekvens i hepatitis b virusgenomet
US20200061030A1 (en) * 2016-10-20 2020-02-27 Aurigene Discovery Technologies Limited Dual inhibitors of vista and pd-1 pathways
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
CN108395443B (zh) * 2017-02-04 2021-05-04 广州丹康医药生物有限公司 抑制程序性死亡受体配体1的环状化合物及其用途
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
TW201841896A (zh) * 2017-04-26 2018-12-01 大陸商南京聖和藥業股份有限公司 作為pd—l1抑制劑的雜環類化合物
CN109096219B (zh) * 2017-06-20 2023-03-21 广州丹康医药生物有限公司 一种新型抗pd-l1化合物、其应用及含其的组合物
WO2019061324A1 (en) 2017-09-29 2019-04-04 Curis Inc. CRYSTALLINE FORMS OF IMMUNOMODULATORS
KR20200068659A (ko) 2017-10-11 2020-06-15 오리진 디스커버리 테크놀로지스 리미티드 3-치환된 1,2,4-옥사다이아졸의 결정질 형태
JP7378394B2 (ja) 2017-11-03 2023-11-13 オーリジーン オンコロジー リミテッド Ｔｉｍ－３およびｐｄ－１経路の二重阻害剤
EP3706798A1 (en) 2017-11-06 2020-09-16 Aurigene Discovery Technologies Limited Conjoint therapies for immunomodulation
CN111315398A (zh) 2017-11-10 2020-06-19 阿尔莫生物科技股份有限公司 白介素-10与免疫检查点途径抑制剂的组合的组合物和使用方法
EP3728283B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
AU2018392212B9 (en) 2017-12-20 2021-03-18 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
WO2019138367A1 (en) 2018-01-12 2019-07-18 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
SG11202007646UA (en) 2018-02-13 2020-09-29 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
CN111788204B (zh) 2018-02-26 2023-05-05 吉利德科学公司 作为hbv复制抑制剂的取代吡咯嗪化合物
US20210379024A1 (en) * 2018-03-14 2021-12-09 Aurigene Discovery Technologies Limited Method of modulating tigit and pd-1 signalling pathways using 1,2,4-oxadiazole compounds
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
CN108586549A (zh) * 2018-05-31 2018-09-28 成都市科隆化学品有限公司 一种Fmoc-Thr(tBu)-OH的制备方法
EP3810109A4 (en) 2018-05-31 2022-03-16 Peloton Therapeutics, Inc. COMPOSITIONS AND METHODS FOR INHIBITING CD73
EP3810189A1 (en) 2018-06-19 2021-04-28 Armo Biosciences, Inc. Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
TWI732245B (zh) 2018-07-13 2021-07-01 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
CN111057069B (zh) * 2018-10-16 2024-01-26 武汉光谷通用名药物研究院有限公司 一种环状化合物、其应用及组合物
CN112955435A (zh) 2018-10-24 2021-06-11 吉利德科学公司 Pd-1/pd-l1抑制剂
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
JP7460644B2 (ja) 2018-10-31 2024-04-02 ギリアード サイエンシーズ， インコーポレイテッド Ｈｐｋ１阻害剤としての置換６－アザベンゾイミダゾール化合物
BR112021008781A2 (pt) * 2018-11-08 2021-08-03 Aurigene Discovery Technologies Limited combinação de inibidores de cd-47 de pequena molécula com outros agentes anticâncer
US20220096518A1 (en) 2018-12-21 2022-03-31 Aim Immunotech Inc. Compositions and methods for cancer therapy
AU2020231115A1 (en) 2019-03-07 2021-08-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
EP3934757B1 (en) 2019-03-07 2023-02-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
EP4017476A1 (en) 2019-08-19 2022-06-29 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
CN111909108B (zh) * 2019-09-02 2023-05-02 中国药科大学 联苯类化合物及其制备方法和医药用途
CA3149557A1 (en) 2019-09-30 2021-04-08 Scott J. Balsitis Hbv vaccines and methods treating hbv
WO2021067644A1 (en) 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
CN116057068A (zh) 2019-12-06 2023-05-02 精密生物科学公司 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶
AU2021237718B2 (en) 2020-03-20 2023-09-21 Gilead Sciences, Inc. Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
BR112022022335A2 (pt) 2020-05-05 2023-01-10 Teon Therapeutics Inc Moduladores de receptor canabinoide tipo 2 (cb2) e usos dos mesmos
CA3204162A1 (en) 2021-01-11 2022-07-14 Robert Kastelein Compositions and methods related to receptor pairing
AU2022274607A1 (en) 2021-05-13 2023-11-16 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates
KR20240019283A (ko) 2021-06-11 2024-02-14 길리애드 사이언시즈, 인코포레이티드 Mcl-1 저해제와 항암제의 병용
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117480155A (zh) 2021-06-23 2024-01-30 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3222439A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
TW202325306A (zh) 2021-09-02 2023-07-01 美商天恩治療有限公司 改良免疫細胞之生長及功能的方法
WO2023081730A1 (en) 2021-11-03 2023-05-11 Teon Therapeutics, Inc. 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
WO2023097211A1 (en) 2021-11-24 2023-06-01 The University Of Southern California Methods for enhancing immune checkpoint inhibitor therapy
WO2024015372A1 (en) 2022-07-14 2024-01-18 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1557852A (en) * 1922-08-15 1925-10-20 Lauerman Clarence Haines Galvanized-iron ventilator
US3227725A (en) 1962-04-17 1966-01-04 Union Carbide Corp Certain 3,5-disubstituted 1,2,4-oxadiazole compounds
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
TW201311B (el) 1991-06-17 1993-03-01 Hoffmann La Roche
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
AU1739099A (en) * 1994-03-08 1999-05-20 American Home Products Corporation Effector proteins of rapamycin
CA2143246C (en) * 1994-03-16 2000-08-22 Thierry Godel Imidazodiazepines
ES2206965T3 (es) 1997-07-29 2004-05-16 Alcon Laboratories, Inc. Composiciones oftalmicas que contienen polimeros de galactomanana y borato.
WO1999038504A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
MXPA02001877A (es) 1999-08-23 2002-08-20 Dana Farber Cancer Inst Inc Pd-1, un receptor para b7-4, y usos del mismo.
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
MXPA03008959A (es) 2001-04-02 2004-10-15 Wyeth Corp Pd-1, un receptor para b7-4 y sus usos.
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
GB0204159D0 (en) 2002-02-22 2002-04-10 British Biotech Pharm Metalloproteinase inhibitors
FI2206517T3 (fi) 2002-07-03 2023-10-19 Ono Pharmaceutical Co Immuunopotentioivia koostumuksia käsittäen anti-PD-L1 -vasta-aineita
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
PL1654002T5 (pl) 2003-08-07 2014-06-30 Allergan Inc Kompozycje do dostarczania środków terapeutycznych do oczu
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US7569578B2 (en) * 2003-12-05 2009-08-04 Bristol-Meyers Squibb Company Heterocyclic anti-migraine agents
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EP1593671A1 (en) 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG DPP-IV inhibitors
WO2006067532A1 (en) 2004-12-24 2006-06-29 Prosidion Ltd G-protein coupled receptor agonists
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2006133216A2 (en) 2005-06-06 2006-12-14 Smithkline Beecham Corporation 4-substituted arylamine derivatives and their use in pharmaceutical compositions
AU2006331731A1 (en) 2005-12-20 2007-07-05 Merck Sharp & Dohme Corp. Niacin receptor agonists, compositions containing such compounds and methods of treatment
US8748627B2 (en) 2006-02-15 2014-06-10 Abbvie Inc. Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
JP2009544625A (ja) 2006-07-20 2009-12-17 メーメット・カーラマン Ｒｈｏキナーゼのベンゾチオフェン阻害剤
AU2007300542B2 (en) 2006-09-25 2012-05-17 Ptc Therapeutics, Inc. Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
AU2008266951B2 (en) 2007-06-18 2013-12-12 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor PD-1
JP2010532385A (ja) 2007-07-02 2010-10-07 ユ，ミン 複合的癌治療の方法、組成物および標的
US7868001B2 (en) 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
ATE551342T1 (de) 2008-02-22 2012-04-15 Irm Llc Heterocyclische verbindungen und zusammensetzungen als c-kit- und pdgfr- kinasehemmer
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010033701A2 (en) 2008-09-19 2010-03-25 Genzyme Corporation Inhibitors of sphingosine kinase 1
JP2012507563A (ja) * 2008-10-30 2012-03-29 エリクシアー ファーマシューティカルズ， インコーポレイテッド スルホンアミド含有化合物およびその使用
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
WO2011137587A1 (en) 2010-05-06 2011-11-10 Hutchison Medipharma Limited Cytokine inhibitors
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012129564A2 (en) 2011-03-24 2012-09-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Proteasome chymotrypsin-like inhibition using pi-1833 analogs
EP2717895A1 (en) 2011-06-08 2014-04-16 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
MX342326B (es) 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
CA2853967A1 (en) * 2011-11-03 2013-05-10 F. Hoffmann-La Roche Ag 8-fluorophthalazin-1 (2h) -one compounds as inhibitors of btk activity
MX2014005289A (es) * 2011-11-03 2014-05-30 Hoffmann La Roche Compuestos de piperazina alquilados.
ES2552514T3 (es) * 2011-11-03 2015-11-30 Hoffmann-La Roche Ag Compuestos bicíclicos de piperazina
WO2013132317A1 (en) 2012-03-07 2013-09-12 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
AU2013239366A1 (en) 2012-03-29 2014-10-16 Aurigene Discovery Technologies Limited Immunomodulating cyclic compounds from the BC loop of human PD1
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
EP2906684B8 (en) 2012-10-10 2020-09-02 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
NZ631762A (en) 2013-01-09 2017-02-24 Gilead Sciences Inc 5-membered heteroaryls and their use as antiviral agents
ES2665619T3 (es) 2013-03-14 2018-04-26 Novartis Ag 3-Pirimidin-4-il-oxazolidin-2-onas como inhibidores de IDH mutante
WO2014147586A1 (en) 2013-03-22 2014-09-25 Novartis Ag 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
ES2788848T3 (es) 2013-09-06 2020-10-23 Aurigene Discovery Tech Ltd Derivados de 1,2,4-oxadiazol como inmunomoduladores
SG11201601679TA (en) 2013-09-06 2016-04-28 Aurigene Discovery Tech Ltd 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
SG11201601844TA (en) 2013-09-13 2016-04-28 Beigene Ltd Anti-pd1 antibodies and their use as therapeutics and diagnostics
WO2016073470A1 (en) 2014-11-04 2016-05-12 The University Of Kansas Lkb1-ampk activators for therapeutic use in polycystic kidney disease
CA2979161A1 (en) 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
EA034708B1 (ru) * 2015-03-10 2020-03-10 Ауриджен Дискавери Текнолоджис Лимитед 1,2,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов
WO2016142852A1 (en) 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
WO2018047143A1 (en) 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Vista signaling pathway inhibitory compounds useful as immunomodulators
US20200061030A1 (en) 2016-10-20 2020-02-27 Aurigene Discovery Technologies Limited Dual inhibitors of vista and pd-1 pathways
WO2019061324A1 (en) 2017-09-29 2019-04-04 Curis Inc. CRYSTALLINE FORMS OF IMMUNOMODULATORS
KR20200068659A (ko) 2017-10-11 2020-06-15 오리진 디스커버리 테크놀로지스 리미티드 3-치환된 1,2,4-옥사다이아졸의 결정질 형태
JP7378394B2 (ja) 2017-11-03 2023-11-13 オーリジーン オンコロジー リミテッド Ｔｉｍ－３およびｐｄ－１経路の二重阻害剤
EP3706798A1 (en) 2017-11-06 2020-09-16 Aurigene Discovery Technologies Limited Conjoint therapies for immunomodulation

Also Published As

Publication number Publication date
WO2016142833A1 (en) 2016-09-15
IL254040B2 (en) 2024-02-01
EP3267984A4 (en) 2019-03-13
US11465976B2 (en) 2022-10-11
HRP20220258T1 (hr) 2022-04-29
CN107427477A (zh) 2017-12-01
JP7325483B2 (ja) 2023-08-14
ES2907988T3 (es) 2022-04-27
EP3267984A1 (en) 2018-01-17
PL3267984T4 (pl) 2022-05-02
AU2021204220A1 (en) 2021-07-15
IL254040B1 (en) 2023-10-01
MX2020003735A (es) 2022-01-14
JP7325483B6 (ja) 2023-08-28
AU2016230793A1 (en) 2017-09-07
CA2979137A1 (en) 2016-09-15
JP2021193100A (ja) 2021-12-23
US10781189B2 (en) 2020-09-22
US20200361880A1 (en) 2020-11-19
AU2024200257A1 (en) 2024-02-01
HK1247814A1 (zh) 2018-10-05
BR112017019303A2 (pt) 2018-05-08
MX2017011618A (es) 2018-03-23
CU20170119A7 (es) 2018-07-05
CA3220902A1 (en) 2016-09-15
US20230110077A1 (en) 2023-04-13
LT3267984T (lt) 2022-03-25
CN107427477B (zh) 2021-11-26
CA2979137C (en) 2023-12-19
HUE058274T2 (hu) 2022-07-28
EP3267984B1 (en) 2021-11-24
PH12017501454A1 (en) 2018-01-15
JP2023178515A (ja) 2023-12-15
AU2021204220B2 (en) 2023-10-19
JP6815686B2 (ja) 2021-01-20
CU24509B1 (es) 2021-05-12
KR20170123640A (ko) 2017-11-08
US20180044303A1 (en) 2018-02-15
IL305546A (en) 2023-10-01
IL254040A0 (en) 2017-10-31
PT3267984T (pt) 2022-03-03
EA201791626A1 (ru) 2018-08-31
CN114213356A (zh) 2022-03-22
CN114159430A (zh) 2022-03-11
RS62960B1 (sr) 2022-03-31
JP2018507890A (ja) 2018-03-22
EA034708B1 (ru) 2020-03-10
MY196130A (en) 2023-03-16
DK3267984T3 (da) 2022-03-07
SG11201706908PA (en) 2017-09-28
JP2020196720A (ja) 2020-12-10
PL3267984T3 (pl) 2022-05-02
SG10202108921VA (en) 2021-09-29
NZ734650A (en) 2023-07-28
EP4023645A1 (en) 2022-07-06
AU2016230793B2 (en) 2021-03-25
SI3267984T1 (sl) 2022-04-29
CN114044760A (zh) 2022-02-15
JP6937090B2 (ja) 2021-09-22

Similar Documents

Publication Publication Date Title
CY1125161T1 (el) Ενωσεις 1,2,4-οξαδιαζολιου και θειαδιαζολιου ως ανοσορρυθμιστες
CY1120899T1 (el) Παραγωγα 1,2,4-οξαδιαζολιου ως ανοσοτροποποιητες
CY1120747T1 (el) Κυκλικες πεπτιδομιμητικες ενωσεις ως ανοσοτροποποιητες
PH12017501452A1 (en) 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
PH12017501455A1 (en) 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
EA201791634A1 (ru) 3-замещенные 1,3,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов
CY1120769T1 (el) Παραγωγα 1,3,4-οξαδιαζολιου και 1,3,4-θειαδιαζολιου ως ανοσοτροποποιητες
PH12017501456A1 (en) Therapeutic cyclic compounds as immunomodulators
EA201990997A1 (ru) Двойные ингибиторы vista и путей pd-1
CY1120988T1 (el) Παρεμποδιστες διαρυλ κινασης
CY1123776T1 (el) Μεθοδοι για την αντιμετωπιση καταστασεων που συνδεονται με την ενεργοποιηση συμπληρωματος εξαρτωμενου απο την μasp-2
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
PH12020550511A1 (en) Dual inhibitors of tim-3 and pd-1 pathways
CL2017000103A1 (es) Derivados de bis(aril)catecol como herbicidas
EA201691549A1 (ru) Ариллактамные ингибиторы киназы
CY1123076T1 (el) Ενωσεις βενζο-ν-υδροξυ αμιδιου που εχουν αντικαρκινικη δραστikothta
EA202090087A3 (ru) 1,2,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов
EA201992045A1 (ru) Ингибиторы pd-1/pd-l1